AR068057A1 - Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. - Google Patents

Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.

Info

Publication number
AR068057A1
AR068057A1 ARP080103461A ARP080103461A AR068057A1 AR 068057 A1 AR068057 A1 AR 068057A1 AR P080103461 A ARP080103461 A AR P080103461A AR P080103461 A ARP080103461 A AR P080103461A AR 068057 A1 AR068057 A1 AR 068057A1
Authority
AR
Argentina
Prior art keywords
alkyl
branched
linear
phenyl
cycloalkyl
Prior art date
Application number
ARP080103461A
Other languages
English (en)
Spanish (es)
Inventor
Maurizio Delcanale
Gabriele Armari
Elisabetta Armani
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR068057A1 publication Critical patent/AR068057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP080103461A 2007-08-08 2008-08-07 Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. AR068057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114019A EP2022783A1 (en) 2007-08-08 2007-08-08 "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"

Publications (1)

Publication Number Publication Date
AR068057A1 true AR068057A1 (es) 2009-11-04

Family

ID=38754730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103461A AR068057A1 (es) 2007-08-08 2008-08-07 Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.

Country Status (37)

Country Link
US (7) US7923565B2 (cg-RX-API-DMAC10.html)
EP (3) EP2022783A1 (cg-RX-API-DMAC10.html)
JP (3) JP2010535722A (cg-RX-API-DMAC10.html)
KR (1) KR101200683B1 (cg-RX-API-DMAC10.html)
CN (1) CN101796028B (cg-RX-API-DMAC10.html)
AR (1) AR068057A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008286027B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0814065B8 (cg-RX-API-DMAC10.html)
CA (1) CA2695580C (cg-RX-API-DMAC10.html)
CL (1) CL2008002330A1 (cg-RX-API-DMAC10.html)
CO (1) CO6290760A2 (cg-RX-API-DMAC10.html)
CY (2) CY1117324T1 (cg-RX-API-DMAC10.html)
DK (2) DK2947068T3 (cg-RX-API-DMAC10.html)
EA (1) EA017530B1 (cg-RX-API-DMAC10.html)
ES (2) ES2655816T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20125537B (cg-RX-API-DMAC10.html)
HR (2) HRP20160292T1 (cg-RX-API-DMAC10.html)
HU (2) HUE035557T2 (cg-RX-API-DMAC10.html)
IL (2) IL203712A (cg-RX-API-DMAC10.html)
JO (1) JO3181B1 (cg-RX-API-DMAC10.html)
LT (1) LT2947068T (cg-RX-API-DMAC10.html)
MA (1) MA31586B1 (cg-RX-API-DMAC10.html)
ME (1) ME00974B (cg-RX-API-DMAC10.html)
MX (1) MX2010001544A (cg-RX-API-DMAC10.html)
MY (1) MY152692A (cg-RX-API-DMAC10.html)
NO (1) NO2947068T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ583103A (cg-RX-API-DMAC10.html)
PE (1) PE20090698A1 (cg-RX-API-DMAC10.html)
PL (2) PL2947068T3 (cg-RX-API-DMAC10.html)
PT (2) PT2185515E (cg-RX-API-DMAC10.html)
RS (2) RS56765B1 (cg-RX-API-DMAC10.html)
SI (2) SI2185515T1 (cg-RX-API-DMAC10.html)
TN (1) TN2010000044A1 (cg-RX-API-DMAC10.html)
TW (1) TWI444366B (cg-RX-API-DMAC10.html)
UA (1) UA99622C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009018909A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201000832B (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
HRP20180488T1 (hr) 2010-04-21 2018-07-13 Chiesi Farmaceutici S.P.A. Postupak priprave čestica sa smanjenim elektrostatičkim nabojem
CA2807406C (en) 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
SI2600830T1 (en) * 2010-08-03 2018-05-31 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
ES2704688T3 (es) * 2010-09-30 2019-03-19 Chiesi Farm Spa Uso de estearato de magnesio en formulaciones de polvo seco para inhalación
EP2718267B1 (en) 2011-06-06 2016-08-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN103889972A (zh) * 2011-10-21 2014-06-25 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
IN2014DN10239A (cg-RX-API-DMAC10.html) 2012-06-04 2015-08-07 Chiesi Farma Spa
HK1212988A1 (zh) 2012-12-05 2016-07-22 奇斯药制品公司 作为pde-4抑制剂的苯基乙基吡啶衍生物
AR093796A1 (es) * 2012-12-05 2015-06-24 Chiesi Farm Spa Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa
KR20150091061A (ko) 2012-12-05 2015-08-07 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
WO2014086852A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Phenylethylpyridine derivatives as pde4-inhibitors
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
JP6458957B2 (ja) 2013-10-22 2019-01-30 チエシ ファルマスティスィ エス．ピー．エー． Ｐｄｅ４阻害剤の製造方法
AR098621A1 (es) 2013-12-05 2016-06-01 Chiesi Farm Spa Derivados de heteroarilo
HK1225384A1 (zh) * 2013-12-05 2017-09-08 奇斯药制品公司 用於治疗呼吸病的二苯甲基衍生物
EP3152202B1 (en) * 2014-06-04 2018-11-28 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors and muscarinic m3 receptor antagonists
EP3152203A1 (en) * 2014-06-04 2017-04-12 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
US9763924B2 (en) * 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
TW201710254A (zh) * 2015-06-01 2017-03-16 吉斯藥品公司 胺基酯衍生物
MA51413A (fr) 2017-12-28 2021-04-28 Chiesi Farm Spa Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique
EP3960457A4 (en) 2019-04-26 2022-05-04 Fuji Corporation PRINT PARAMETER ACQUISITION DEVICE AND PRINT PARAMETER ACQUISITION METHOD
US12247674B2 (en) * 2021-01-18 2025-03-11 Chad Heffernan Eclipse valve assembly
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
JP2025514863A (ja) 2022-04-27 2025-05-09 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐｄｅ４阻害剤の新規結晶形態
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
CN119947705A (zh) 2022-09-22 2025-05-06 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
EP4590273A1 (en) 2022-09-22 2025-07-30 Chiesi Farmaceutici S.p.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
PL307265A1 (en) * 1992-07-28 1995-05-15 Rhone Poulenc Rorer Ltd Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
ATE217611T1 (de) 1996-09-17 2002-06-15 Merck & Co Inc Verfahren zur herstellung von phosphodiesterase iv inhibitoren
EP1157007A1 (en) 1999-02-25 2001-11-28 Merck Frosst Canada Inc. Pde iv inhibiting compounds, compositions and methods of treatment
KR20050111759A (ko) 2003-03-12 2005-11-28 셀진 코포레이션 7-아미노-이소인돌릴 화합물 및 그의 제약학적 용도
US20060239927A1 (en) * 2003-03-31 2006-10-26 Kyowa Hakko Kogyo Co., Drug for airway administration
US7888381B2 (en) * 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
SI2600830T1 (en) 2010-08-03 2018-05-31 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
CA2807406C (en) 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
EP2718267B1 (en) 2011-06-06 2016-08-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN103889972A (zh) 2011-10-21 2014-06-25 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
IN2014DN10239A (cg-RX-API-DMAC10.html) 2012-06-04 2015-08-07 Chiesi Farma Spa

Also Published As

Publication number Publication date
KR20100050501A (ko) 2010-05-13
MA31586B1 (fr) 2010-08-02
IL239466A0 (en) 2015-07-30
EP2947068A1 (en) 2015-11-25
MX2010001544A (es) 2010-03-15
BRPI0814065B1 (pt) 2020-02-11
CA2695580A1 (en) 2009-02-12
SI2185515T1 (sl) 2016-04-29
US20090048220A1 (en) 2009-02-19
UA99622C2 (ru) 2012-09-10
US20120116091A1 (en) 2012-05-10
GEP20125537B (en) 2012-05-25
EP2947068B1 (en) 2017-11-08
US20130137648A1 (en) 2013-05-30
CY1117324T1 (el) 2017-04-26
HRP20160292T1 (hr) 2016-04-22
US9102619B2 (en) 2015-08-11
EA017530B1 (ru) 2013-01-30
US20110144070A1 (en) 2011-06-16
US20150018321A1 (en) 2015-01-15
HK1145686A1 (en) 2011-04-29
AU2008286027A1 (en) 2009-02-12
WO2009018909A2 (en) 2009-02-12
ZA201000832B (en) 2011-04-28
RS54606B1 (sr) 2016-08-31
JP2010535722A (ja) 2010-11-25
AU2008286027A2 (en) 2010-04-01
JO3181B1 (ar) 2018-03-08
US20140135301A1 (en) 2014-05-15
CN101796028A (zh) 2010-08-04
AU2008286027B2 (en) 2013-02-21
HUE027171T2 (en) 2016-10-28
ES2563478T3 (es) 2016-03-15
CO6290760A2 (es) 2011-06-20
DK2185515T3 (en) 2016-02-29
US20110144075A1 (en) 2011-06-16
WO2009018909A3 (en) 2009-05-14
EP2185515A2 (en) 2010-05-19
DK2947068T3 (en) 2018-01-15
KR101200683B1 (ko) 2012-11-13
US8203000B2 (en) 2012-06-19
BRPI0814065A2 (pt) 2015-01-06
US9000177B2 (en) 2015-04-07
EA201000149A1 (ru) 2010-08-30
JP2015163629A (ja) 2015-09-10
PT2947068T (pt) 2018-01-12
CN101796028B (zh) 2013-07-10
JP2014037426A (ja) 2014-02-27
JP5746298B2 (ja) 2015-07-08
PL2185515T3 (pl) 2016-06-30
MY152692A (en) 2014-11-28
TWI444366B (zh) 2014-07-11
EP2022783A1 (en) 2009-02-11
TW200916440A (en) 2009-04-16
TN2010000044A1 (en) 2011-09-26
ME00974B (me) 2012-06-20
ES2655816T3 (es) 2018-02-21
LT2947068T (lt) 2018-01-25
US8383826B2 (en) 2013-02-26
CY1119669T1 (el) 2018-04-04
CA2695580C (en) 2016-10-04
US7923565B2 (en) 2011-04-12
NO2947068T3 (cg-RX-API-DMAC10.html) 2018-04-07
PT2185515E (pt) 2016-03-31
PE20090698A1 (es) 2009-07-06
JP6023846B2 (ja) 2016-11-09
RS56765B1 (sr) 2018-04-30
HUE035557T2 (en) 2018-05-02
EP2185515B1 (en) 2016-01-06
CL2008002330A1 (es) 2009-03-20
BRPI0814065B8 (pt) 2021-05-25
IL203712A (en) 2016-08-31
PL2947068T3 (pl) 2018-04-30
SI2947068T1 (en) 2018-02-28
NZ583103A (en) 2012-03-30
HRP20180212T1 (hr) 2018-03-09

Similar Documents

Publication Publication Date Title
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
SI2751083T1 (en) Quinolone compound
AR086676A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR091023A1 (es) Inhibidores del nampt
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
JP2013529196A5 (cg-RX-API-DMAC10.html)
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR090994A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration